TICKERNERD
Menu
CRDFCRDFHealthcare · Biotechnology

CRDF Stock Forecast: Cardiff Oncology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.88
−3.15% on the day

The 7 Wall Street analysts covering Cardiff Oncology, Inc. hold a median 12-month price target of $4 — +354.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$68.5M
Ticker Nerd rank
42 / 100
Median analyst target
$4.00
Analysts covering
7
Total return, dividends reinvested
1W
−8.3%
1M
+4.8%
YTD
−68.7%
1Y
−61.1%
From 52W high
−72.6%
From 52W low
+8.7%
$0.81
$3.21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRDF stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardiff Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Size
80
Revisions
73
Issuance
62
Accruals
58
Volatility
17
Quality
16
Value
14
Momentum
5

Growth (89): Sales and profits are climbing, and climbing faster than before.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRDF stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRDF, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26CRDFHigh $12.00Median $4.00Low $1.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
3 Buy4 Hold0 Sell
Low $1.20Median $4.00High $12.00

The green dot is the last close — the median target sits +354.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026William BlairDowngradeMarket Perform—
3 June 2026Craig-HallumDowngradeHold—
3 June 2026Craig-HallumDowngradeHold$10 → $2.00
1 June 2026HC Wainwright & Co.DowngradeNeutral—
1 June 2026HC Wainwright & Co.DowngradeNeutral—
1 June 2026TD CowenDowngradeHold—
1 June 2026TD CowenDowngradeHold—
25 Feb 2026Piper SandlerMaintainsOverweight—
28 Jan 2026HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025HC Wainwright & Co.MaintainsBuy—
8 July 2025Ladenburg ThalmannInitiatesBuy—
24 June 2025JefferiesInitiatesHold—
9 May 2025HC Wainwright & Co.MaintainsBuy—
28 Feb 2025HC Wainwright & Co.MaintainsBuy—
13 Dec 2024Piper SandlerMaintainsOverweight—
8 Nov 2024HC Wainwright & Co.MaintainsBuy—
6 Sept 2024Craig-HallumInitiatesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
6 Mar 2024HC Wainwright & Co.MaintainsBuy—
1 Mar 2024Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRDF appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRDF analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Cardiff Oncology, Inc. (CRDF) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 83% of US stocks

Price / sales
141.1×

Cheaper than 4% of US stocks

Price / book
2.4×

Cheaper than 42% of US stocks

EV / EBITDA
−0.9×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−14.1%

Higher than 13% of US stocks

Earnings growth (YoY)
−62.4%

Higher than 7% of US stocks

Gross margin
—
Operating margin
−9245.2%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−94.1%

Higher than 14% of US stocks

Return on assets
−46.7%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRDF vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRDFCardiff Oncology, Inc.$68.5M
42
MNOVMediciNova, Inc.$68.3M
94
CSBRChampions Oncology, Inc.$68.4M
47
BOLDBoundless Bio, Inc.$67.2M
74
SPROSpero Therapeutics, Inc.$68.7M
83
EXOZeXoZymes, Inc.$66.4M
11
XBITXBiotech, Inc.$69.5M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardiff Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRDF news & analysis

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

GlobeNewsWire · 11 Aug 2026positive

Cardiff Oncology reported its second quarter 2026 results and provided a business update. The company also announced that positive Phase 2 CRDF-004 data, presented in an oral session at ASCO, support advancing 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.

Why it matters — A CRDF watcher would care because the positive data and the planned move into a registrational program represent a key step forward for the company's lead drug candidate in a defined patient population.

FAQ

Frequently asked questions about CRDF stock

What is the CRDF stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Cardiff Oncology, Inc. have a median 12-month price target of $4, with estimates ranging from $1.2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRDF stock a buy right now?

Of the 7 analysts covering Cardiff Oncology, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardiff Oncology, Inc. 42 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRDF?

As at 22 Aug 2026, Cardiff Oncology, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will CRDF stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +354.5% from the last close, and Ticker Nerd's factor model ranks Cardiff Oncology, Inc. 42 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRDF stock forecast for 2030?

No analyst covering Cardiff Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRDF are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $12 over the next 12 months.

How has CRDF stock performed over the past year?

Cardiff Oncology, Inc. returned -61.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardiff Oncology, Inc. do?

Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for cancers with significant unmet needs.

What is the latest news on CRDF?

The most recent item we track (GlobeNewsWire, 11 Aug 2026): "Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update". Cardiff Oncology reported its second quarter 2026 results and provided a business update. The company also announced that positive Phase 2 CRDF-004 data, presented in an oral session at ASCO, support advancing 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.

Company

About Cardiff Oncology, Inc.

Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for cancers with significant unmet needs. Its lead candidate, onvansertib, is an oral, selective polo-like kinase 1 (PLK1) inhibitor primarily targeting RAS-mutated metastatic colorectal cancer (mCRC) in combination with standard-of-care chemotherapy and targeted therapies. The company advances clinical programs in this indication via its randomized Phase 2 CRDF-004 trial, evaluating onvansertib in first-line treatment settings. Additional efforts include investigator-initiated trials exploring onvansertib in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer. Cardiff Oncology Inc. operates exclusively in the United States, concentrating on oncology therapeutics that disrupt mitosis in cancer cells. Headquartered in San Diego, California, and founded in 1999, it plays a role in addressing challenging cancer subtypes through innovative targeted treatments.

CEO Dr. Mani Mohindru Ph.D. · 30 employees · United States · https://www.cardiffoncology.com